

PATENT

Docket No.: 01662/579022

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

APPLICANTS:

MENDELOVICI et al.

SERIAL NO.:

10/662,986

FILED:

September 15, 2003

FOR:

NOVEL SULFONATION METHOD FOR ZONISAMIDE INTERMEDIATE

IN ZONISAMIDE SYNTHESIS AND THEIR NOVEL CRYSTAL FORMS

GROUP ART UNIT:

1626

EXAMINER:

Rebecca L. Anderson

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). The paragraphs marked below are applicable. It is believed that no fees other than those indicated below are due, but authorization is hereby given to charge any additional fees due, or to credit any overpayment, to deposit account 11-0600.

1. This Information Disclosure Statement is being filed (a) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. §1.53(d), (b) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, (c) before the mailing date of a first Office Action on the merits in the present application, OR (d) before the mailing of a first office action after filing of a request for continued examination. No certification or fee is required.

the me	erits, b	This Information Disclosure Statement is being filed more than three the U.S. filing date AND after the mailing date of the first Office Action on ut before the mailing date of a final action, Notice of Allowance, or any therwise closes prosecution.
	foreig month	a. I hereby certify that each item of information contained in this nation Disclosure Statement was first cited in a communication from a n patent office in a counterpart foreign application not more than three as prior to the filing of this Information Disclosure Statement. 37 CFR (e)(1).
	in a co inquir three	b. I hereby certify that no item of information in this Information osure Statement was cited in a communication from a foreign patent office ounterpart foreign application or, to my knowledge after making reasonable y, was known to any individual designated in 37 CFR §1.56(c) more than months prior to the filing of this Information Disclosure Statement. 37 CFR (e)(2).
	the di	c. Please debit Deposit Account No. 11-0600 in the amount of 00 in payment of the fee under 37 CFR §1.17(p) to ensure consideration of sclosed information. Two duplicate copies of this paper are attached. 37 §1.97(c)(2).
before Disclo amour	e paym sure S nt of \$1 leration	This Information Disclosure Statement is being filed after the mailing date ion, Notice of Allowance or an action that otherwise closes prosecution, but ent of the Issue Fee. Applicant(s) hereby request(s) that the Information tatement be considered. Please debit Deposit Account No. 11-0600 in the 180.00 in payment of the petition fee under 37 CFR §1.17(p) to ensure n of the disclosed information. Two duplicate copies of this paper are
	foreig month	a. I hereby certify that each item of information contained in this nation Disclosure Statement was first cited in a communication from a n patent office in any counterpart foreign application not more than three ns prior to the filing of this Information Disclosure Statement. 37 CFR (e)(1).
	in a co inquiry three	b. I hereby certify that no item of information in this Information sure Statement was cited in a communication from a foreign patent office cunterpart foreign application or, to my knowledge after making reasonable y, was known to any individual designated in 37 CFR §1.56(c) more than months prior to the filing of this Information Disclosure Statement. 37 CFR (e)(2).
☐ preser	4. nt spec	Relevance of the non-English language reference(s) is discussed in the sification.
☐ Englis inform		The reference(s) was/were cited in a counterpart foreign application. An uage version of the foreign search report is attached for the Examiner's

reference(s) appears in the Appendix attached here					
7. The Examiner's attention is directed to Applications Nos. 10/233,190 filed August 29, 2002 10/288,135 filed November 5, 2002 with copies of the and 10/662, 966 filed September 15, 2003 with a conditional directed to related technical subject matter. Copies not been attached because the present application application no. 10/233,190. These co-pending appropriously rejected claim similar to at least one claim Examiner is respectfully requested to consider the therein during examination of the present application	with a copy of the claims attached; the specification and claims attached; opy of the claims attached, which are s of 10/233,190 and 10/662,966 have and 10/662,966 are divisionals of clications may contain at least one im of the present application. The cited applications and the art cited				
☐ 8. This application is one of a series of rattached Appendix, which are directed to related to identification of those U.S. Patent Applications is no secrecy as to those applications now or upon issuapatent. The Examiner is respectfully requested to the art cited therein during the examination.	echnical subject matter. The ot to be construed as a waiver of ance of the present application as a				
9. The reference(s) was/were cited by o application No, filed, what date under 35 U.S.C. §120. Thus, copies of these §1.98(d).					
☐ 10. English-language Abstracts of the no attached hereto.	on-English language references are				
☐ 11. Since this application was filed after June 30, 2003, copies of U.S. references are not included.					
	Respectfully submitted,				
	KENYON & KENYON				
Date: August 19, 2004	King Lit Wong King Lit Wong Registration No. 37,500				
KLW/Imq					
Kenyon & Kenyon 1500 K Street, N.W. Washington, D.C. 20005 Telephone: (202) 220-4200 Facsimile: (202) 220-4201					

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO NFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

US-US-US-US-

Complete if Known Application Number 10/662,986 Filing Date September 15, 2003 First Named Inventor Mendelovici et al. Art Unit 1626 Examiner Name Rebecca L. Anderson 01662/579022 Attorney Docket Number

Sheet 1		of 1	Attorney Docket Number		01662	01662/579022	
			U.S. PATENT	DOCUMENTS	-		
Examiner Initials *	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Appl Cited Document			
	No.1	Number - Kind Code ² (if known)			ent	Passages or Relevant Figures Appear	
-	}				·		

		FOREIGN PA	TENT DOCUME	NTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ - Kind Code ⁵ (<i>il known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [€]
		NON PATENT LIT	ERATURE DOCUM	ENTS		
Examiner Cite Initials * No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), value number(s), publisher, city and/or country where published.				ge(s), volume-issue	T ²	
		MENDELOVICI et al., Claims from U.S. Patent Application No. 10/233,190, filed August 29, 2002, "Novel Sulfonation Method for Zonisamide Intermediate in Zonisamide Synthesis and Their Novel Crystal Forms," 3 pp.				
	NIDAM et al., U.S. Patent Application, Publication No. 2003/0144527, Pub. Date: July 31, 2003; Application No. 10/288,135, filed November 5, 2002, "Novel Sulfonation Method for Zonisamide Intermediate in Zonisamide Synthesis and Their Novel Crystal Forms," 35 pp.					
	NIDAM et al., Pending claims from U.S. Patent Application No. 10/288,135, filed November 5, 2002, "Novel Sulfonation Method for Zonisamide Intermediate in Zonisamide Synthesis and Their Novel Crystal Forms," 2 pp.					
	MENDELOVICI et al., Pending claims from U.S. Patent Application No. 10/662,966, filed September 15, 2003, "Novel Sulfonation Method for Zonisamide Intermediate in Zonisamide Synthesis and Their Novel Crystal Forms," 3 pp.					

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. § Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. § Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.